重症患者干扰素γ-1b的3个月结局与成本效果:PREV-HAP试验二次分析
该研究为嵌入多中心、安慰剂对照、随机试验PREV-HAP的成本效果分析,纳入109例接受机械通气的重症成人,比较干扰素γ-1b与安慰剂,采用集体视角、90天时间 horizon,主要结局为每获得一个调整质量调整生命年(QALY)的增量成本效果比(ICER)。90天全因死亡率干扰素组23.6%、安慰剂组25%(OR=0.88,95%CI 0.40-1.93,p=0.67);每例患者90天平均调整成本差为-1638欧元(95%CI -17534至11968),利于干扰素γ-1b;调整QALY均差为+0.019(95%CI -0.005至0.043)。在每QALY支付意愿2万至15万欧元区间,基础案例分析中干扰素γ-1b具有成本效果的概率为0.60至0.71。作者认为早期使用干扰素γ可能具有成本效果,支持开展进一步研究,但因PREV-HAP提前终止导致样本量小,结果外推需谨慎。
要点
- 机械通气重症成人90天全因死亡率:干扰素γ-1b组23.6% vs 安慰剂组25%,OR=0.88(95%CI 0.40-1.93),p=0.67,无显著差异。
- 每例患者90天平均调整成本差为-1638欧元(95%CI -17534至11968),方向利于干扰素γ-1b。
- 干扰素γ-1b组与安慰剂组调整QALY均差为+0.019(95%CI -0.005至0.043)。
- 每QALY支付意愿2万至15万欧元时,基础案例分析中干扰素γ-1b具有成本效果的概率为0.60至0.71。
- 作者认为早期使用干扰素γ可能具有成本效果,支持开展其他研究;因PREV-HAP提前终止致样本量小,结果外推需谨慎。
适用人群与场景
- PREV-HAP试验纳入的重症成人,接受机械通气。
处置流程与药物剂量
- 干扰素γ-1b与安慰剂比较,早期给药;原文未写明具体剂量、给药途径、频次或疗程。
研究设计与关键结果
- 研究设计:成本效果分析(CEA)嵌入多中心、安慰剂对照、随机试验PREV-HAP,采用集体视角、90天时间 horizon,主要结局为每获得一个调整QALY的增量成本效果比(ICER),QALY由患者和代理应答者填写EQ-5D-3L估算。
- 样本量:PREV-HAP试验109例患者纳入成本效果分析。
- 90天全因死亡率:干扰素组23.6% vs 安慰剂组25%,OR=0.88(95%CI 0.40-1.93),p=0.67。
- 每例患者90天平均调整成本差:-1638欧元(95%CI -17534至11968),利于干扰素γ-1b。
- 调整QALY均差:干扰素γ-1b组 vs 安慰剂组为+0.019(95%CI -0.005至0.043)。
- 成本效果概率:每QALY支付意愿2万至15万欧元时,基础案例分析中干扰素γ-1b具有成本效果的概率为0.60至0.71。
证据类型、等级与局限
- 证据类型:多中心、安慰剂对照、随机试验PREV-HAP的二次成本效果分析。
- 局限:作者指出,因PREV-HAP提前终止导致样本量小,结果的推广应谨慎考虑;作者结论支持开展其他关于该治疗的研究。
对床旁实践的改变
- 作者认为,早期使用干扰素γ可能对重症患者具有成本效果,支持开展其他关于该治疗的研究。
- 作者指出,鉴于PREV-HAP提前终止导致样本量小,结果的推广应谨慎考虑。
指南或共识出处
- PREV-HAP试验,ClinicalTrials.gov标识符NCT04793568,注册日期2021年2月24日。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Interferon gamma‑1b has been proposed to treat critical illness-induced immunosuppression. We aimed to determine the effects on 90-day outcomes and the cost-effectiveness of interferon gamma‑1b compared to placebo in mechanically ventilated critically ill patients.
METHODS: A cost-effectiveness analysis (CEA) was embedded in the "PREV-HAP trial", a multicenter, placebo‑controlled, randomized trial, which randomly assigned critically ill adults under mechanical ventilation to receive interferon gamma or placebo. The CEA compared interferon-gamma with placebo using a collective perspective at a 90-day time horizon. The primary outcome was the incremental cost-effectiveness ratio (ICER) expressed in terms of adjusted cost per adjusted Quality-Adjusted Life-Years (QALYs) gained. QALYs were estimated from the responses of patients and proxy respondents to the health-related quality of life questionnaire EQ-5D-3L.
RESULTS: The 109 patients in the PREV-HAP trial were included in the CEA. At day 90, all-cause mortality rates were 23.6% in the interferon group and 25% in the placebo group (Odds Ratio (OR) = 0.88 (0.40 -1.93) p = 0.67). The difference in the mean adjusted costs per patient at 90 days was €-1.638 (95%CI €-17.534 to €11.968) in favor of interferon gamma-1b. The mean difference in adjusted QALYs between interferon gamma-1b and the placebo group was + 0.019 (95%CI -0.005 to 0.043). The probability that interferon gamma-1b was cost-effective ranged from 0.60 to 0.71 for a willingness to pay a QALY between €20k and €150k for the base case analysis.
CONCLUSION: Early administration of interferon gamma might be cost-effective in critically ill patients supporting the realization of other studies on this treatment. However, the generalization of the findings should be considered cautiously, given the small sample size due to the premature end of PREV-HAP. Trial registration ClinicalTrials.gov Identifier: NCT04793568, Registration date: 2021-02-24.
参考来源
- Bouras M, Tessier P, Poulain C, et al. Three-month outcomes and cost-effectiveness of interferon gamma-1b in critically ill patients: a secondary analysis of the PREV-HAP trial. J Intensive Care. 2024. PMID: 39394183. doi:10.1186/s40560-024-00753-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。